 Guardant Health Incs NASDAQ: GH Q1 FY22 revenues rose 22 YY to 96.1 million, beating the consensus of 95.70 million. Guardants precision oncology testing revenues grew 32 to 84.1 million, driven by the increase in clinical and biopharma testing. 